1. Academic Validation
  2. Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia

Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia

  • Bioorg Med Chem. 2020 Jul 1;28(13):115489. doi: 10.1016/j.bmc.2020.115489.
Aya Futamura 1 Ryo Suzuki 1 Yunoshin Tamura 1 Hiroshi Kawamoto 1 Mari Ohmichi 2 Noriko Hino 1 Yuichi Tokumaru 1 Sora Kirinuki 1 Tetsuaki Hiyoshi 1 Takeshi Aoki 1 Daiji Kambe 1 Dai Nozawa 3
Affiliations

Affiliations

  • 1 Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.
  • 2 Drug Safety and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan.
  • 3 Discovery Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama 331-9530, Japan. Electronic address: d-nozawa@taisho.co.jp.
Abstract

Here, we present the design, synthesis, and SAR of dual orexin 1 and 2 receptor antagonists, which were optimized by balancing the antagonistic activity for orexin receptors and lipophilicity. Based on the prototype compound 1, ring construction and the insertion of an additional heteroatom into the resulting ring led to the discovery of orexin 1 and 2 receptor antagonists, which were 3-benzoyl-1,3-oxazinane derivatives. Within these derivatives, (-)-3h enabled a high dual orexin receptor antagonistic activity and a low lipophilicity. Compound (-)-3h exhibited potent sleep-promoting effects at a po dose of 1 mg/kg in a rat polysomnogram study, and optimal PK properties with a rapid Tmax and short half-lives in rats and dogs were observed, indicating a predicted human half-life of 0.9-2.0 h. Thus, (-)-3h (ORN0829; investigation code name, TS-142) was selected as a viable candidate and is currently in clinical development for the treatment of insomnia.

Keywords

DORA; Dual orexin receptor antagonist; Insomnia.

Figures
Products